CD19 and B-cell chronic lymphocytic leukemia: Lastly, the BiTE targeting CD47 and CD19, TG-1801, is currently being investigated for several hematological malignancies (including CLL) as a monotherapy or combined with ublituximab (anti-CD20 antibody); however, to this date, there are no data available (NCT04806035) [118].